CHD5 and ovarian carcinoma: In addition, CHD5 mutations have been implicated in head and neck squamous cell carcinoma [22], human prostate cancer [23], ovarian cancer [24], ovarian clear cell carcinoma [25], cutaneous melanoma [26], hepatocellular carcinoma [27], neuroblastomas [28], metastatic prostate tumors [29], breast cancer and colorectal cancers [30].